Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
INTS6L antisense RNA 1 (INTS6L-AS1) is a long non-coding RNA (lncRNA) gene, also known as DDX26B-AS1, that produces an RNA transcript but does not encode a protein[3]. As an antisense RNA, it is transcribed from the DNA strand opposite to its neighboring genes (such as INTS6L or DDX26B), and it may have regulatory effects at the RNA level—typically influencing gene expression, chromatin structure, or RNA stability in cis (on neighboring genes) or trans (elsewhere in the genome)[2]. However, for INTS6L-AS1, there is currently no direct evidence supporting its function as a therapeutic target or established disease role. No known drugs interact with this lncRNA, and there is no evidence for its use as a biomarker or any known safety concerns. The molecule is primarily classified as a non-coding regulatory RNA, not as a receptor, enzyme, transporter, or other canonical drug target[3].
Acts as a long non-coding antisense RNA, potentially modulating gene expression via RNA interaction; exact mechanisms for INTS6L-AS1 not elucidated[2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on INTS6L antisense RNA 1 (non-protein coding) (INTS6L-AS1).